So much could be said here at this stage, referencing comments...

So much could be said here at this stage, referencing comments made by certain posters regarding trial design, penny stock, insider trading, major shareholders, public statements made by the company, "glass-of-water" references, etc.

Or we can now focus on the importance of conducting a RCT:


https://clinicaltrials.gov/study/NCT05643638?term=cynata&checkSpell=false&rank=1

Cynata's inclusion criteria is aiming to enrol patients that provide enough data points by implementing the "Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines":



Given the implementation of the above before the trial commences, should avoid the need to perform (multiple) post-hoc analysis and subsequently ending up with too little data points to show a connection of the treatment based on data points collected before and throughout the trial.

And just as a reminder, the timing to commence MSC treatment will likely play a vital role here:



https://hotcopper.com.au/threads/ann-fda-clears-cynata-ind-for-phase-2-trial-in-gvhd.6763678/?post_id=66220575

Where is it at?



https://company-announcements.copyright link/asx/cyp/40b8ba4d-29b2-11ee-9e97-fef68616d084.pdf

Time for KK to announce that the trial centers in the US are open for recruitment!